- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 281/18 - Cycles à huit chaînons
Détention brevets de la classe C07D 281/18
Brevets de cette classe: 17
Historique des publications depuis 10 ans
|
1
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Neurovive Pharmaceutical AB | 15 |
2 |
| Merck Sharp & Dohme LLC | 3720 |
2 |
| Bristol-myers Squibb Company | 4845 |
1 |
| AstraZeneca UK Limited | 676 |
1 |
| FUJIFILM Corporation | 28960 |
1 |
| Alfa Wassermann S.p.A. | 20 |
1 |
| Phenex Pharmaceuticals AG | 22 |
1 |
| Rutgers, The State University of New Jersey | 1850 |
1 |
| Salix Pharmaceuticals, Ltd. | 47 |
1 |
| Santen Pharmaceutical Co., Ltd. | 611 |
1 |
| State of Oregon acting by and through the State Board of Higher Education on behalf of Portland State University | 8 |
1 |
| Tomoegawa Co., Ltd. | 247 |
1 |
| Ube Industries, Ltd. | 866 |
1 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2802 |
1 |
| Cothera BioScience, Inc. | 15 |
1 |
| Autres propriétaires | 0 |